Biomea Fusion Inc., a clinical-stage company specializing in diabetes and obesity, has announced a public offering of its common stock and accompanying warrants. The offering includes shares, pre-funded warrants, and common stock warrants, all to be sold by Biomea. The company has also provided underwriters with a 30-day option to purchase an additional 15% of the shares and pre-funded warrants. The offering is being conducted under an effective shelf registration statement filed with the U.S. Securities and Exchange Commission. Jefferies is serving as the sole book-running manager for this offering, which is expected to close around June 20, 2025, subject to customary conditions.